Immunosuppressive and cytotoxic drugs in dermatology.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D001380:Azauridine / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D002699:Chlorambucil / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D012871:Skin Diseases / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D003561:Cytarabine; D001761:Bleomycin; D002699:Chlorambucil; D003609:Dactinomycin; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D001380:Azauridine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D001379:Azathioprine; D006918:Hydroxyurea; D008727:Methotrexate